ELE-Ket+ for MDD

Eleusis is planning to conduct a Phase II study investigating using ELE-Ket+ as a treatment for major depressive disorder (MDD).

ELE-Ket+ is a combination infusion therapy that includes ketamine.

The trial is set to begin in at the end of 2021. At present, no information is available regarding the status of the trial.

Topic Depression
Compound Ketamine
Country United States of America
Visit trial
Status Planned
Results Published
Design Open
Type Interventional
Generation First
Sex All
Therapy No

Trial Details

Eleusis is planning to conduct a Phase II study investigating using ELE-Ket+ as a treatment for major depressive disorder (MDD). ELE-Ket+ is a combination infusion therapy that includes ketamine.

NCT Number

Sponsors & Collaborators

Eleusis
Eleusis is a clinical-stage life sciences company that studies and develops psychedelic drugs for therapeutic use. Since 2013 the company has been researching psychedelics and is now developing ELE-Psilo (psilocybin) for depression that is in Phase I.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.
?>